Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer

hope or reality from clinical studies

Patrizia Vici, Laura Pizzuti, Luciano Mariani, G. Zampa, Daniele Santini, Luigi Di Lauro, T. Gamucci, C. Natoli, Paolo Marchetti, Maddalena Barba, Marcello Maugeri-Saccà, Domenico Sergi, Federica Tomao, Enrico Vizza, S. Di Filippo, Francesca Paolini, Gianfranca Curzio, Giacomo Corrado, A. Michelotti, Giuseppe Sanguineti & 3 others Antonio Giordano, Ruggero Marchiano De Maria, Aldo Venuti

Research output: Contribution to journal › Review article

Abstract

Human papillomavirus (HPV) is widely known as a cause of cervical cancer (CC) and cervical intraepithelial neoplasia (CIN). HPVs related to cancer express two main oncogenes, i.e. E6 and E7, considered as tumorigenic genes; their integration into the host genome results in the abnormal regulation of cell cycle control. Due to their peculiarities, these oncogenes represent an excellent target for cancer immunotherapy. In this work the authors highlight the potential use of therapeutic vaccines as safe and effective pharmacological tools in cervical disease, focusing on vaccines that have reached the clinical trial phase. Many therapeutic HPV vaccines have been tested in clinical trials with promising results. Adoptive T-cell therapy showed clinical activity in a phase II trial involving advanced CC patients. A phase II randomized trial showed clinical activity of a nucleic acid-based vaccine in HPV16 or HPV18 positive CIN. Several trials involving peptide-protein-based vaccines and live-vector based vaccines demonstrated that these approaches are effective in CIN as well as in advanced CC patients. HPV therapeutic vaccines must be regarded as a therapeutic option in cervical disease. The synergic combination of HPV therapeutic vaccines with radiotherapy, chemotherapy, immunomodulators or immune checkpoint inhibitors opens a new and interesting scenario in this disease.

Original languageEnglish
Pages (from-to)1327-1336
Number of pages10
JournalExpert Review of Vaccines
Volume15
Issue number10
DOIs
Publication statusPublished - Oct 2 2016

Fingerprint

Papillomavirus Vaccines
Uterine Cervical Neoplasms
Cervical Intraepithelial Neoplasia
Vaccines
Oncogenes
Clinical Trials
DNA Vaccines
Immunologic Factors
Therapeutic Uses
Therapeutics
Cell- and Tissue-Based Therapy
Cell Cycle Checkpoints
Immunotherapy
Neoplasms
Radiotherapy
Randomized Controlled Trials
Genome
Pharmacology
T-Lymphocytes
Drug Therapy

Keywords

  • cervical cancer
  • cervical intraepithelial neoplasia
  • Human papillomavirus
  • immunotherapy
  • therapeutic vaccines

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer : hope or reality from clinical studies. / Vici, Patrizia; Pizzuti, Laura; Mariani, Luciano; Zampa, G.; Santini, Daniele; Di Lauro, Luigi; Gamucci, T.; Natoli, C.; Marchetti, Paolo; Barba, Maddalena; Maugeri-Saccà, Marcello; Sergi, Domenico; Tomao, Federica; Vizza, Enrico; Di Filippo, S.; Paolini, Francesca; Curzio, Gianfranca; Corrado, Giacomo; Michelotti, A.; Sanguineti, Giuseppe; Giordano, Antonio; De Maria, Ruggero Marchiano; Venuti, Aldo.

In: Expert Review of Vaccines, Vol. 15, No. 10, 02.10.2016, p. 1327-1336.

Research output: Contribution to journal › Review article

Vici, P, Pizzuti, L, Mariani, L, Zampa, G, Santini, D, Di Lauro, L, Gamucci, T, Natoli, C, Marchetti, P, Barba, M, Maugeri-Saccà, M, Sergi, D, Tomao, F, Vizza, E, Di Filippo, S, Paolini, F, Curzio, G, Corrado, G, Michelotti, A, Sanguineti, G, Giordano, A, De Maria, RM & Venuti, A 2016, 'Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies', Expert Review of Vaccines, vol. 15, no. 10, pp. 1327-1336. https://doi.org/10.1080/14760584.2016.1176533
Vici P, Pizzuti L, Mariani L, Zampa G, Santini D, Di Lauro L et al. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Review of Vaccines. 2016 Oct 2;15(10):1327-1336. https://doi.org/10.1080/14760584.2016.1176533
Vici, Patrizia ; Pizzuti, Laura ; Mariani, Luciano ; Zampa, G. ; Santini, Daniele ; Di Lauro, Luigi ; Gamucci, T. ; Natoli, C. ; Marchetti, Paolo ; Barba, Maddalena ; Maugeri-Saccà, Marcello ; Sergi, Domenico ; Tomao, Federica ; Vizza, Enrico ; Di Filippo, S. ; Paolini, Francesca ; Curzio, Gianfranca ; Corrado, Giacomo ; Michelotti, A. ; Sanguineti, Giuseppe ; Giordano, Antonio ; De Maria, Ruggero Marchiano ; Venuti, Aldo. / Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer : hope or reality from clinical studies. In: Expert Review of Vaccines. 2016 ; Vol. 15, No. 10. pp. 1327-1336.
@article{9bf4c2587d1e42f0b1fbf5c1cae297d3,
title = "Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies",
abstract = "Human papillomavirus (HPV) is widely known as a cause of cervical cancer (CC) and cervical intraepithelial neoplasia (CIN). HPVs related to cancer express two main oncogenes, i.e. E6 and E7, considered as tumorigenic genes; their integration into the host genome results in the abnormal regulation of cell cycle control. Due to their peculiarities, these oncogenes represent an excellent target for cancer immunotherapy. In this work the authors highlight the potential use of therapeutic vaccines as safe and effective pharmacological tools in cervical disease, focusing on vaccines that have reached the clinical trial phase. Many therapeutic HPV vaccines have been tested in clinical trials with promising results. Adoptive T-cell therapy showed clinical activity in a phase II trial involving advanced CC patients. A phase II randomized trial showed clinical activity of a nucleic acid-based vaccine in HPV16 or HPV18 positive CIN. Several trials involving peptide-protein-based vaccines and live-vector based vaccines demonstrated that these approaches are effective in CIN as well as in advanced CC patients. HPV therapeutic vaccines must be regarded as a therapeutic option in cervical disease. The synergic combination of HPV therapeutic vaccines with radiotherapy, chemotherapy, immunomodulators or immune checkpoint inhibitors opens a new and interesting scenario in this disease.",
keywords = "cervical cancer, cervical intraepithelial neoplasia, Human papillomavirus, immunotherapy, therapeutic vaccines",
author = "Patrizia Vici and Laura Pizzuti and Luciano Mariani and G. Zampa and Daniele Santini and {Di Lauro}, Luigi and T. Gamucci and C. Natoli and Paolo Marchetti and Maddalena Barba and Marcello Maugeri-Sacc{\`a} and Domenico Sergi and Federica Tomao and Enrico Vizza and {Di Filippo}, S. and Francesca Paolini and Gianfranca Curzio and Giacomo Corrado and A. Michelotti and Giuseppe Sanguineti and Antonio Giordano and {De Maria}, {Ruggero Marchiano} and Aldo Venuti",
year = "2016",
month = "10",
day = "2",
doi = "10.1080/14760584.2016.1176533",
language = "English",
volume = "15",
pages = "1327--1336",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer

T2 - hope or reality from clinical studies

AU - Vici, Patrizia

AU - Pizzuti, Laura

AU - Mariani, Luciano

AU - Zampa, G.

AU - Santini, Daniele

AU - Di Lauro, Luigi

AU - Gamucci, T.

AU - Natoli, C.

AU - Marchetti, Paolo

AU - Barba, Maddalena

AU - Maugeri-Saccà, Marcello

AU - Sergi, Domenico

AU - Tomao, Federica

AU - Vizza, Enrico

AU - Di Filippo, S.

AU - Paolini, Francesca

AU - Curzio, Gianfranca

AU - Corrado, Giacomo

AU - Michelotti, A.

AU - Sanguineti, Giuseppe

AU - Giordano, Antonio

AU - De Maria, Ruggero Marchiano

AU - Venuti, Aldo

PY - 2016/10/2

Y1 - 2016/10/2

N2 - Human papillomavirus (HPV) is widely known as a cause of cervical cancer (CC) and cervical intraepithelial neoplasia (CIN). HPVs related to cancer express two main oncogenes, i.e. E6 and E7, considered as tumorigenic genes; their integration into the host genome results in the abnormal regulation of cell cycle control. Due to their peculiarities, these oncogenes represent an excellent target for cancer immunotherapy. In this work the authors highlight the potential use of therapeutic vaccines as safe and effective pharmacological tools in cervical disease, focusing on vaccines that have reached the clinical trial phase. Many therapeutic HPV vaccines have been tested in clinical trials with promising results. Adoptive T-cell therapy showed clinical activity in a phase II trial involving advanced CC patients. A phase II randomized trial showed clinical activity of a nucleic acid-based vaccine in HPV16 or HPV18 positive CIN. Several trials involving peptide-protein-based vaccines and live-vector based vaccines demonstrated that these approaches are effective in CIN as well as in advanced CC patients. HPV therapeutic vaccines must be regarded as a therapeutic option in cervical disease. The synergic combination of HPV therapeutic vaccines with radiotherapy, chemotherapy, immunomodulators or immune checkpoint inhibitors opens a new and interesting scenario in this disease.

AB - Human papillomavirus (HPV) is widely known as a cause of cervical cancer (CC) and cervical intraepithelial neoplasia (CIN). HPVs related to cancer express two main oncogenes, i.e. E6 and E7, considered as tumorigenic genes; their integration into the host genome results in the abnormal regulation of cell cycle control. Due to their peculiarities, these oncogenes represent an excellent target for cancer immunotherapy. In this work the authors highlight the potential use of therapeutic vaccines as safe and effective pharmacological tools in cervical disease, focusing on vaccines that have reached the clinical trial phase. Many therapeutic HPV vaccines have been tested in clinical trials with promising results. Adoptive T-cell therapy showed clinical activity in a phase II trial involving advanced CC patients. A phase II randomized trial showed clinical activity of a nucleic acid-based vaccine in HPV16 or HPV18 positive CIN. Several trials involving peptide-protein-based vaccines and live-vector based vaccines demonstrated that these approaches are effective in CIN as well as in advanced CC patients. HPV therapeutic vaccines must be regarded as a therapeutic option in cervical disease. The synergic combination of HPV therapeutic vaccines with radiotherapy, chemotherapy, immunomodulators or immune checkpoint inhibitors opens a new and interesting scenario in this disease.

KW - cervical cancer

KW - cervical intraepithelial neoplasia

KW - Human papillomavirus

KW - immunotherapy

KW - therapeutic vaccines

UR - http://www.scopus.com/inward/record.url?scp=84987790585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987790585&partnerID=8YFLogxK

U2 - 10.1080/14760584.2016.1176533

DO - 10.1080/14760584.2016.1176533

M3 - Review article

VL - 15

SP - 1327

EP - 1336

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 10

ER -

Access to Document